Diagnosis, prognosis and therapeutic control of malignant diseases using PLA2R1 methylation analysis
The invention relates to the field of medicine, specifically to the diagnostics, prognosis and therapy control of tumour diseases. The invention is based on the hitherto unknown epigenetic silencing, discovered by chance by the inventors, of the phospholipase-A2-receptor-1-coding gene in leukaemia cells and in patients suffering from leukaemias and solid tumours. Based on this finding, the invention provides methods and a kit with which the degree of methylation of the phospholipase-A2-receptor-1 gene in an isolated sample of the patient is determined.
Property right: DE102010031354B3; WO002012007462A1
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A chip unique in the world
A team from UPV and iPRONICS has manufactured the first universal, programmable and multifunctional photonic chip on the market. A team from the Photonics Research Laboratory (PRL)-iTEAM of the Universitat…
Advance in light-based computing
…shows capabilities for future smart cameras. UCLA-developed experimental device demonstrates ability to reduce glare in images. Researchers developing the next generation of computing technology aim to bring some light to…
Evidence for reversible oxygen ion movement during electrical pulsing
…enabler of the emerging ferroelectricity in binary oxides. In a recent study published in Materials Futures, researchers have uncovered a pivotal mechanism driving the emergence of ferroelectricity in binary oxides….
